Studies of OrthoLogic's Chrysalin(R) (TP508) Show Specific Receptor Binding Activity and Effects in Human Endothelial Cells
11 Dicembre 2006 - 3:00PM
PR Newswire (US)
SAN DIEGO, Dec. 11 /PRNewswire-FirstCall/ -- OrthoLogic Corp.
(NASDAQ:OLGC) today announced results of experiments that advance
the basic science supporting its novel synthetic peptide Chrysalin
(TP508). Two posters are being presented at the American Society
for Cell Biology 46th Annual Meeting in San Diego, CA (December 9 -
13, 2006). "The experiments being presented at this year's ASCB
Annual Meeting help to further our understanding of the basic
science behind this exciting molecule," said Darrell H. Carney,
Ph.D., Professor of Biochemistry and Molecular Biology at The
University of Texas Medical Branch, Galveston. "We have gained
greater insight into how TP508 stimulates repair and
revascularization of tissues; we believe that endothelial cells
play a key role in a number of TP508 effects." The first
presentation demonstrates binding and chemical cross-linking of
TP508 to specific molecules on the surface of endothelial cells.
This is the first identification of what may be a specific TP508
receptor. It therefore represents a significant step in
understanding how TP508 activates cells. Dr. Carney and colleagues
have explored the signals that are stimulated by TP508 binding to
endothelial cells. Their studies, as described in the second
presentation, show that TP508 increases the ability of endothelial
cells to produce nitric oxide and that TP508 prevents negative
effects caused by oxygen deprivation, a condition found in
myocardial ischemia and chronic wounds. This discovery may provide
a unifying hypothesis to explain how TP508 stimulates tissue
repair, and raises the possibility that TP508 could be useful in
treating a number of vascular diseases associated with aging where
endothelial cells fail to produce nitric oxide. About the Receptor
Binding Presentation "Demonstration of Specific Binding of TP508 to
Receptors on Fibroblasts and Coronary Artery Endothelial Cells by
Photo-Affinity Cross-Linking" TP508 is a non-proteolytic synthetic
peptide representing the portion of human thrombin originally
identified as the fibroblast high-affinity receptor binding domain.
TP508 initiates cellular effects distinct from those of
proteolytically active thrombin and has been postulated to bind a
non-proteolytically activated thrombin receptor (NPAR). TP508 has
been shown to accelerate revascularization and repair of animal
tissues and to accelerate healing of bone fractures (based on x-ray
evidence) and diabetic foot ulcers. The data presented show that
TP508 specifically binds to one or more cell surface receptors. The
data also provide initial characterization of receptor molecules
that appear to be distinct from the PAR1 thrombin receptor. Ongoing
characterization and sequencing will provide additional answers to
advance the understanding of how these molecules relate to TP508
signaling. About the eNOS Presentation "Thrombin Peptide, TP508,
Upregulates Expression and Activation of eNOS and Prevents
Hypoxia-Induced eNOS Downregulation in Human Endothelial Cells"
TP508 is being evaluated in preclinical tests for potential use in
myocardial revascularization and other vascular indications. In
animal models, TP508 accelerates repair and revascularization of
dermal and musculoskeletal tissue and increases the density of
blood vessels in ischemic myocardium. This abstract describes
experiments in which the authors studied the effects of TP508 on
endothelial cell nitric oxide (NO) signaling and the enzyme that
produces NO (eNOS). Impaired NO production reduces the
responsiveness of endothelial cells to angiogenic factors and
causes loss of endothelial function in ischemic and inflamed blood
vessels contributing to a number of chronic diseases. The authors
hypothesized that TP508 may accelerate tissue repair by stimulating
NO production or restoring the ability of dysfunctional cells to
make NO. If so, TP508 may have potential therapeutic value in
tissues and diseases exhibiting endothelial dysfunction. The
studies show that in human coronary artery endothelial cells, TP508
increased phosphorylation of eNOS. This effect of TP508 was
observed in normal cells and those cultured in low oxygen. TP508
also increased eNOS expression and prevented low oxygen-induced
decreases in eNOS expression. Therefore, TP508 may exert its
effects in a number of tissues by modulating eNOS activity and NO
production in endothelial cells. About OrthoLogic OrthoLogic is a
biotechnology company committed to developing a pipeline of novel
therapeutic peptides and other molecules aimed at helping patients
with under-served medical conditions. The Company is focused on the
development and commercialization of two product platforms:
Chrysalin(R) (TP508) and AZX100. Chrysalin, the Company's novel
synthetic 23-amino acid peptide, is being studied in two lead
indications, both of which represent areas of significant unmet
medical need -- fracture repair and diabetic foot ulcer healing.
Based on the Company's pioneering scientific research of the
natural healing cascade, OrthoLogic has become a leading company
focused on bone and tissue repair. The Company owns exclusive
worldwide rights to Chrysalin. AZX100 is a novel synthetic
pre-clinical 24-amino acid peptide, one of a new class of compounds
in the field of smooth muscle relaxation called Intracellular Actin
Relaxing Molecules, or ICARMs(TM). AZX100 is currently being
evaluated for commercially significant medical applications, such
as the treatment of vasospasm associated with subarachnoid
hemorrhage, the prevention of keloid scarring and the treatment of
asthma. OrthoLogic has an exclusive worldwide license to AZX100.
OrthoLogic's corporate headquarters are in Tempe, Arizona. For more
information, please visit the Company's website:
http://www.orthologic.com/. Statements in this press release or
otherwise attributable to OrthoLogic regarding our business that
are not historical facts are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements, which include the timing and
acceptability of FDA filings and the efficacy and marketability of
potential products, involve risks and uncertainties that could
cause actual results to differ materially from predicted results.
These risks include: delays in obtaining or inability to obtain
FDA, institutional review board or other regulatory approvals of
pre-clinical or clinical testing; unfavorable outcomes in our
pre-clinical and clinical testing; the development by others of
competing technologies and therapeutics that may have greater
efficacy or lower cost; delays in obtaining or inability to obtain
FDA or other necessary regulatory approval of our products; our
inability to successfully and cost effectively develop or outsource
manufacturing and marketing of any products we are able to bring to
market; changes in FDA or other regulations that affect our ability
to obtain regulatory approval of our products, increase our
manufacturing costs or limit our ability to market our products;
our possible need for additional capital in the future to fund the
continued development of our product candidates; and other factors
discussed in our Form 10-K for the fiscal year ended December 31,
2005, and other documents we file with the Securities and Exchange
Commission. DATASOURCE: OrthoLogic Corp. CONTACT: Investors,
Melanie Friedman of Stern Investor Relations, Inc.,
+1-212-362-1200, , for OrthoLogic Corp. Web site:
http://www.orthologic.com/
Copyright
Grafico Azioni Orthologic (MM) (NASDAQ:OLGC)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Orthologic (MM) (NASDAQ:OLGC)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Orthologic (MM) (NASDAQ): 0 articoli recenti
Più Orthologic (MM) Articoli Notizie